PRLD

Prelude Therapeutics Incorporated

3.34 USD

Last updated Dec 9, 04:55 UTC

Yesterday HIGH

$3.34

Yesterday LOW

$2.86

52w HIGH

$8.56

52w LOW

$1.66

EPS

-0.45

PE

-7.42

Next Earnings

Mar 13, 2024

Overview News Government Trades

Prelude Therapeutics Incorporated stock is up 10.6% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 December’s closed higher than November.

Prelude Therapeutics Incorporated focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

preludetx.com

Benzinga Newsdesk

Wed May 17, 2023

Prelude Therapeutics Reports Launch Of Proposed $100M Public Offering Of Shares Of Common Stock

The company has commenced an underwritten public offering of $100.0 million of shares of common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase shares of
Happy Mohamed

Mon May 8, 2023

Prelude Therapeutics Q1 EPS $(0.58) Beats $(0.68) Estimate

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.68) by 14.71 percent. This is a 7.94 percent increase over losses of $(0.63) per share
richadhand@benzinga.com

Fri Mar 17, 2023

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $17

HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a Buy and raises the price target from $15 to $17.
Happy Mohamed

Wed Mar 15, 2023

Prelude Therapeutics Q4 EPS $(0.60) Beats $(0.63) Estimate

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.63) by 4.76 percent. This is a 15.49 percent increase over losses of $(0.71) per share
Bill Haddad

Wed Mar 15, 2023

Prelude Therapeutics Announces Clinical Trial Collaboration With BeiGene To Evaluate PRT2527 In Combination With Zanubrutinib In Hematologic Cancers
Lisa Levin

Tue Jan 3, 2023

Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.
Michael Horton

Wed Dec 7, 2022

Prelude Therapeutics Shares Resume Trade
Benzinga Newsdesk

Wed Dec 7, 2022

Prelude Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down 23.4%
Lisa Levin

Tue Nov 22, 2022

Carvana, Crocs And Other Big Losers From Monday

U.S. stocks closed lower on Monday, with the Nasdaq dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session.
Priya Nigam

Mon Nov 21, 2022

Why This Prelude Therapeutics Analyst Disagrees With 2 Others And Downgraded The Stock

Shares of Prelude Therapeutics Inc (NASDAQ: PRLD) came under pressure during early trading on Monday.